Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518350 | 0.81 | PIK3CA (0.49) | KDRPIK3CA | |
| SCHEMBL3486298 | 0.79 | PIK3CA (0.40) | CSNK1DKDRCSNK1EPIK3CA | |
| SCHEMBL6312547 | 0.78 | MAP3K5 (0.46) | GSK3BDYRK1AMAP3K5 | |
| SCHEMBL3486218 | 0.78 | MAP3K5 (0.61) | GSK3BCSNK1DCSNK1EMAP3K5 | |
| SCHEMBL2517479 | 0.77 | PIK3CG (0.43) | CSNK1DKDRCSNK1EPIK3CA | |
| SCHEMBL2516313 | 0.77 | PIK3CG (0.45) | CSNK1DKDRCSNK1EPIK3CA | |
| SCHEMBL2516569 | 0.77 | PIK3CG (0.46) | CSNK1DCSNK1EPIK3CA | |
| SCHEMBL2519360 | 0.76 | KDR (0.42) | CSNK1DKDRCSNK1E | |
| SCHEMBL16409563 | 0.76 | KDR (0.51) | KDRAAK1 | |
| SCHEMBL245728 | 0.75 | KDR (0.56) | CSNK1DKDRCSNK1EAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230391768-A2 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | TTK 395/4885GSK3B 772/4885DYRK1A 1215/4885 |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | TTK 94/4885GSK3B 76/4885DYRK1A 399/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | TTK 2007/4885GSK3B 35/4885DYRK1A 4332/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | TTK 94/4885GSK3B 76/4885DYRK1A 399/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | TTK 395/4885GSK3B 772/4885DYRK1A 1215/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | TTK 4068/4885GSK3B 1025/4885DYRK1A 4321/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | TTK 395/4885GSK3B 772/4885DYRK1A 1215/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | TTK 4068/4885GSK3B 1025/4885DYRK1A 4321/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | TTK 4127/4885GSK3B 903/4885DYRK1A 4333/4885 |
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | JAK1, JAK2, JAK3 | TTK 71/4885GSK3B 81/4885DYRK1A 247/4885 |
| US-20230391768-A2 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | TTK 91/4885GSK3B 114/4885DYRK1A 302/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | TTK 430/4885GSK3B 815/4885DYRK1A 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.